Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Combo Product Consultations To Be Streamlined

This article was originally published in The Pink Sheet Daily

Executive Summary

Internal assessment finds inter-center collaboration stymied by issues ranging from IT compatibility to resource reimbursement, but FDA says it has a five-point plan to improve the process.

Advertisement

Related Content

Combo Product Safety: US FDA Rule On Postmarket Reporting Nears Finalization
FDA 'Intercenter Institutes' Legislation Headed For Senate Mark-Up
Califf Supports Combo Products Pathway At Confirmation Hearing
Senate Bill Aimed At Streamlining Combo Product Regulation
Combo Product Reforms Are A Priority For Next User Fee Round, FDA Officials Say
Human Factors Questions Drive Rise In FDA Inter-Center Consults

Topics

Advertisement
UsernamePublicRestriction

Register

PS077880

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel